INTERNATIONAL PATENT: SENTI BIOSCIENCES, INC., BLUEROCK THERAPEUTICS LP FILES APPLICATION FOR "SUSTAINED TRANSGENE EXPRESSION OF IMID-RESPONSIVE PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES AND USES THEREOF"

GENEVA, Feb. 11 -- SENTI BIOSCIENCES, INC. (2 Corporate Drive, First FloorSouth San Francisco, California 94080), BLUEROCK THERAPEUTICS LP (238 Main Street, Floor 3Cambridge, Massachusetts 02142) filed a patent application (PCT/US2025/040185) for "SUSTAINED TRANSGENE EXPRESSION OF IMID-RESPONSIVE PEPTIDE-SUICIDE PROTEIN FUSION POLYPEPTIDES AND USES THEREOF" on Jul 31, 2025. With publication no. WO/2026/030634, the details related to the patent application was published on Feb 05, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): HUNG, Michelle Elizabeth (c/o SENTI BIOSCIENCES, INC.2 Corporate ...